Arkolith/Insider Trading/KNSA/Form 4

Ragosa Mark

CHIEF FINANCIAL OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Mar 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.7M
Net Open-Market Flow
-$1.7M
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 9, 2026Option exercise(M)2K$22.89$47K14K
Mar 9, 2026Option exercise(M)11K$17.76$187K25K
Mar 9, 2026Option exercise(M)14K$18.06$249K38K
Mar 9, 2026Option exercise(M)10K$26.74$277K49K
Mar 9, 2026Sell(S)19K$46.24$867K12K
Mar 9, 2026Sell(S)18K$45.58$820K31K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 9, 2026Option exercise(M)2K—$00
Mar 9, 2026Option exercise(M)10K—$023K
Mar 9, 2026Option exercise(M)14K—$019K
Mar 9, 2026Option exercise(M)11K—$018K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001835458-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML